Why the study?
Real-world clinical experience and outcomes of persistent AF ablation using a contact force-sensing catheter had not been fully evaluated in a prospective multicenter setting.
What is the safety and 12-month success rate of persistent atrial fibrillation ablation using a contact force-sensing catheter in a real-world setting?
What is the safety and 12-month success rate of persistent atrial fibrillation ablation using a contact force-sensing catheter in a real-world setting?
In a real-world registry, persistent AF ablation using a contact force-sensing catheter achieved a 63.1% 12-month success rate with a 4.0% primary adverse event rate and significant improvements in quality of life.
Answers are grounded in this paper and cite their sources.
Real-world CF-sensing ablation shows acceptable safety and QoL gains in persAF; leaves open comparative efficacy versus other technologies.
BACKGROUND: To investigate the real-world clinical experience of persistent atrial fibrillation (persAF) ablation using the THERMOCOOL SMARTTOUCH® catheter with contact force (CF)-sensing ability in a prospective, multicenter registry. METHODS: Patients with persAF (excluding long-standing persAF) undergoing ablation were enrolled. Primary adverse events (AEs), 12-month success, quality of life (QoL), and correlation of success with CF were assessed. RESULTS: Overall, 150 patients with persAF (age 61.6 ± 9.4 years; 76.0% male; 90.7% Caucasian; left ventricular ejection fraction 56.9% ± 10.3%; left atrial diameter 41.5 ± 7.9 mm) underwent catheter insertion (safety cohort); 142 met eligibility criteria and were ablated (evaluable cohort). Confirmation of entrance block for all targeted pulmonary veins was achieved in 99.3% of patients. The primary AE rate was 4.0% (6/150), and 12-month success was 63.1% (95% confidence interval: 54.2%-71.4%). A non-significant trend towards higher success was observed in patients with isoproterenol/adenosine challenge vs. those without (73.1% vs. 60.2%, respectively; P=0.065). Investigators stayed within their pre-selected CF working range (catheter-tissue contact stability) 79.7% ± 12.7% of the time. When investigators stayed within the CF range ≥80% vs. <80% of the time, ablation success was 69.2% vs. 58.5%, respectively (P=0.285). QoL improved significantly at 6 months and was sustained through the 12-month follow-up (P<0.0001). CONCLUSIONS: Symptom control in a real-world setting of persAF ablation using the THERMOCOOL SMARTTOUCH® catheter was 63.1%, with significant improvements in QoL, and trended non-significantly towards increased success in patients receiving isoproterenol/adenosine challenge and when investigators stayed within their pre-selected CF range ≥80% of the time.
No takes yet. Share an insight, caveat, or question.
Potter et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: